|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Lymphocyte Subset Panel 5
Test CodeSUBS5
Quest Code
8360
Alias/See Also
CD4
CPT Codes
86361
Includes
% CD4, Absolute CD4+ Cells, Absolute Lymphocytes
Preferred Specimen
5 mL whole blood collected in an EDTA (lavender-top) tube
Minimum Volume
0.5 mL
Instructions
If a CBC is also required, a separate EDTA (lavender-top) tube must be submitted.
Transport Container
5 mL (or 3 mL pediatric) EDTA (lavender-top ) tube
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 72 hours
Refrigerated: Unacceptable
Frozen: Unacceptable
Refrigerated: Unacceptable
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis • Lithium heparin (green-top) tube • ACD (yellow-top) tube • Clotted
Methodology
Flow Cytometry (FC)
FDA Status
This test code is for non-New York patient testing. For New York patient testing, use test code 17332.
Setup Schedule
Nights Mon-fri (specimen must be received by noon of testing day)
Report Available
2 days
Reference Range
See Laboratory Report
Clinical Significance
This panel is used to measure CD4+ T cells (CD4) in the blood (absolute CD4 cell count, %CD4, absolute lymphocytes). The CD4+ T-cell (CD4) count is the most valuable indicator of immune status in HIV-infected individuals. This panel can be used to establish a baseline CD4 level and to monitor treatment progress. It can also be used to facilitate differential diagnoses between congenital and acquired immunodeficiency diseases [1].
A significant reduction in CD4 count can lead to opportunistic infections, and the CD4 cell count/percentage can he used to make decisions regarding opportunistic infection prophylaxis as per guidelines [1].
During the first 2 years of antiretroviral (ARV) therapy, CD4 levels should be tested every 3 to 6 months. Patients who develop viremia while on therapy or whose CD4 count stays below 300 cells/µL should also have their CD4 levels tested every 3 to 6 months. After 2 years of ARV therapy, with consistently suppressed viral load and a CD4 count of 300 to 500 cells/µL, CD4 counts should be tested every 12 months. Note that when CD4 counts are > 500 cells/ µL, CD4 testing is optional [1]. CD4 testing should also be conducted if therapy fails. Refer to current HIV management guidelines for further information on recommended testing frequency [1].
Reference
1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated July 10, 2019. Accessed November 10, 2019.
A significant reduction in CD4 count can lead to opportunistic infections, and the CD4 cell count/percentage can he used to make decisions regarding opportunistic infection prophylaxis as per guidelines [1].
During the first 2 years of antiretroviral (ARV) therapy, CD4 levels should be tested every 3 to 6 months. Patients who develop viremia while on therapy or whose CD4 count stays below 300 cells/µL should also have their CD4 levels tested every 3 to 6 months. After 2 years of ARV therapy, with consistently suppressed viral load and a CD4 count of 300 to 500 cells/µL, CD4 counts should be tested every 12 months. Note that when CD4 counts are > 500 cells/ µL, CD4 testing is optional [1]. CD4 testing should also be conducted if therapy fails. Refer to current HIV management guidelines for further information on recommended testing frequency [1].
Reference
1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated July 10, 2019. Accessed November 10, 2019.
Performing Laboratory
| Quest Diagnostics LLC |
| 200 Forest Street, 3rd Floor, Suite B |
| Marlborough, MA 01752-3023 |
